Top

Published in:

01-03-2018 | Original Article

BCR/ABL analysis in myelodysplastic syndromes

Authors: Omid Kiani Ghale-sardi, Mohammad Ali JalaliFar, Elahe Khodadi, Ahmad Ahmadzadeh, Najmaldin Saki

Published in: Comparative Clinical Pathology | Issue 2/2018

Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders commonly occurring in older patients. Several genetic abnormalities have been observed in these patients, including BCR/ABL fusion, which has been sporadically reported in some papers. In this study, we dealt with evaluating the incidence of BCR/ABL fusion as a diagnostic and prognostic marker for MDS patients. Fifty patients were diagnosed as MDS by morphology and clinical examinations. Cytogenetic and molecular genetic analysis of BCR/ABL fusion was done on bone marrow (BM) biopsy and aspirate using fluorescence in situ hybridization (FISH) and nested-polymerase chain reaction (PCR) techniques, respectively. Descriptive data analysis was done using SPSS software, and Mann-Whitney and independent-sample t test were used to assess the correlation between variables. P210 BCR/ABL fusion was detected in two male patients (4%). Comparison of hematologic indices showed no significant difference between the patients harboring BCR/ABL fusion and to those not harboring it, and BM cellularity was not different between the two groups. MDS patients harboring BCR/ABL fusion did not respond well to conventional MDS treatments but showed a good response to imatinib therapy. Assessment of BCR/ABL fusion in MDS patients can be helpful for the diagnosis and prediction of their response to treatment, but further studies are required to confirm this recommendation.

Bejar R (2015) Myelodysplastic syndromes diagnosis: what is the role of molecular testing? Curr Hematol Malig Rep 10(3):282–291. https://doi.org/10.1007/s11899-015-0270-5 CrossRefPubMedPubMedCentral

Berrebi A, Bruck R, Shtalrid M, Chemke J (1984) Philadelphia chromosome in idiopathic acquired sideroblastic anemia. Actahaematologica 72(5):343–345

Cogle CR, Saki N, Khodadi E, Li J, Shahjahani M, Azizidoost S (2015) Bone marrow niche in the myelodysplastic syndromes. Leuk Res 39(10):1020–1027. https://doi.org/10.1016/j.leukres.2015.06.017 CrossRefPubMed

Dalla Torre CA, de Martino Lee ML, Yoshimoto M, Lopes LF, Melo LN, de Toledo SRC et al (2002) Myelodysplastic syndrome in childhood: report of two cases with deletion of chromosome 4 and the Philadelphia chromosome. Leuk Res 26(6):533–538. https://doi.org/10.1016/S0145-2126(01)00152-7 CrossRefPubMed

Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, et al. (2012) Five-group cytogenetic risk classification, monosomal karyotype and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood. Blood 120(7):1398–408

Drummond M, Lush C, Vickers M, Reid F, Kaeda J, Holyoake T. (2003) Imatinibmesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome. Leukemia 17(2):463–5

Giagounidis A, Haase D (2013) Morphology, cytogenetics and classification of MDS. Best Pract Res Clin Haematol 26(4):337–353. https://doi.org/10.1016/j.beha.2013.09.004 CrossRefPubMed

Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O’Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M (2013) Myelodysplastic syndromes. J Natl Compr Cancer Netw 11(7):838–874. https://doi.org/10.6004/jnccn.2013.0104 CrossRef

Ma X (2012) Epidemiology of myelodysplastic syndromes. Am J Med 125(7):S2–S5. https://doi.org/10.1016/j.amjmed.2012.04.014 CrossRefPubMedPubMedCentral

Nacheva EP, Grace CD, Brazma D, Gancheva K, Howard-Reeves J, Rai L, Gale RE, Linch DC, Hills RK, Russell N, Burnett AK, Kottaridis PD (2013) Does BCR/ABL1 positive acute myeloid leukaemia exist? Br J Haematol 161(4):541–550. https://doi.org/10.1111/bjh.12301 CrossRefPubMed

Neuendorff NR, Schwarz M, Hemmati P, Türkmen S, Bommer C, Burmeister T et al (2014) BCR-ABL1+ acute myeloid leukemia: clonal selection of a BCR-ABL1-subclone as a cause of refractory disease with nilotinib treatment. Actahaematologica 133(2):237–241

Nybakken GE, Bagg A (2014) The genetic basis and expanding role of molecular analysis in the diagnosis, prognosis, and therapeutic design for myelodysplastic syndromes. J MolDiagn 16:145–158

Onozawa M, Fukuhara T, Takahata M, Yamamoto Y, Miyake T, Maekawa IA (2003) Case of myelodysplastic syndrome developed blastic crisis of chronic myelogenous leukemia with acquisition of major BCR/ABL. Ann Hematol 82(9):593–595. https://doi.org/10.1007/s00277-003-0703-4 CrossRefPubMed

Paridar M, Ghalesardi OK, Seghatoleslami M, Ahmadzadeh A, Khosravi A, Saki N (2017) Cytogenetic and molecular basis of BCR-ABL myelodysplastic syndrome: diagnosis and prognostic approach. J Cancer Metastasis and Treat 3(2):38–44. https://doi.org/10.20517/2394-4722.2016.61 CrossRef

Rana A, Ali GM, Ali S, Khan A, Mansoor S, Malik S, Farooqi AA (2013) BCR-ABL1 in leukemia: disguise master outplays riding shotgun. J Cancer Res Ther 9(1):6–10. https://doi.org/10.4103/0973-1482.110339 CrossRefPubMed

Sharathkumar A, Saunders E, Dror Y, Grant R, Greenberg M, Weitzman S et al (2004) Allogeneic bone marrow transplantation vs chemotherapy for children with Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 33(1):39–45. https://doi.org/10.1038/sj.bmt.1704319 CrossRefPubMed

Tala I, Chen R, Hu T, Fitzpatrick ER, Williams DA, Whitehead IP (2013) Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression. Leukemia 27(5):1080–1089. https://doi.org/10.1038/leu.2012.351 CrossRefPubMed

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937–951. https://doi.org/10.1182/blood-2009-03-209262 CrossRefPubMed

Visconte V, Selleri C, Maciejewski JP, Tiu RV (2014) Molecular pathogenesis of myelodysplastic syndromes. Transl Med UniSa 8:19–30PubMedPubMedCentral

Wakayama T, Maniwa Y, Ago H, Kakazu N, Abe TA (2001) Variant form of myelodysplastic syndrome WithPh−minor-BCR/ABL transcript. Int J Hematol 74(1):58–63. https://doi.org/10.1007/BF02982550 CrossRefPubMed

Zhang L, Bennett JM, Zhang X, Moscinski L, Ibarz-Pinilla J, List AF, Komrokji R (2010) Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemia. J Clin Oncol 29(15):e434–e4e6. https://doi.org/10.1200/JCO.2010.31.6265 CrossRefPubMed

Title: BCR/ABL analysis in myelodysplastic syndromes
Authors: Omid Kiani Ghale-sardi
Mohammad Ali JalaliFar
Elahe Khodadi
Ahmad Ahmadzadeh
Najmaldin Saki
Publication date: 01-03-2018
Publisher: Springer London
Published in: Comparative Clinical Pathology / Issue 2/2018
Print ISSN: 1618-5641
Electronic ISSN: 1618-565X
DOI: https://doi.org/10.1007/s00580-017-2602-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

BCR/ABL analysis in myelodysplastic syndromes

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Clinical and pathological findings of enzootic nasal adenocarcinoma of goat

Tumor necrosis factor-α (TNF-α) −308 G/A and lymphotoxin-α (LT-α) +252 A/G genetic polymorphisms in Egyptian acute lymphoblastic leukemia

Serum protein electrophoresis reference values in the gyrfalcon (Falco rusticolus)

Biochemical profiles of hydatid cystic fluid from infected dromedary camels, cattle and goats in Oman

Effect of zinc oxide nanoparticles and Bacillus coagulans as probiotic on growth, histomorphology of intestine, and immune parameters in broiler chickens

Determination of calcium, magnesium, phosphorus, iron, and copper contents in rooster seminal plasma and their effects on semen quality